Welcome to SuperLan Chemical Co.,Ltd.
Home > Products > MAPK > Raf > TAK-632

TAK-632

(CAS No:1228591-30-7)
TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
CAS No:1228591-30-7
Molecular Weight(MW):554.52
Purity:98%+
Specification:500mg;1g;5g;10g;50g;100g
Price and large packaging, please e-mail consultation:info@SuperLan-chem.com
QC Documents
 COA  MSDS  HPLC  NMR
ChemicalInfomation
CAS No: 1228591-30-7
Molecular formula(MF) C27H18F4N4O3S
Molecular Weight(MW): 554.52
Alias
Solubility
In vitro DMSO 100 mg/mL (180.33 mM)
Ethanol 2 mg/mL (3.6 mM)
Water <1 mg/mL
In vivo 2% DMSO+98% PEG 300 5 mg/mL
Biological Activity
Description TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
Features Orally bioavailable, pan-raf inhibitor that targets both wild-type and mutant forms.
Targets
C-Raf [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
1.4 nM 8.3 nM 66 nM 120 nM 280 nM
In vitro

TAK-632 inhibits phosphorylation of MEK and ERK in melanoma A375 cells (BRAFV600E) with IC50 of 12 nM and 16 nM, respectively. In human melanoma HMVII cells (NRASQ61K/BRAFG469V), TAK-632 also shows strong inhibition of pMEK and pERK with IC50 of 49 nM and 50 nM, respectively. Moreover, TAK-632 also exhibits antiproliferative activity in both A375 and HMVII cells with GI50 of 66 nM and 200 nM, respectively. [1] TAK-632 induces RAF dimerization but inhibits the kinase activity of the RAF dimer because of its slow dissociation from RAF. The combination of TAK-632 and TAK-733 exhibits synergistic antiproliferative effects in BRAF- and NRAS-mutated melanoma cells. [2]

In vivo TAK-632 shows superior oral bioavailability in both rats and dogs. TAK-632 (3.9–24.1 mg/kg, p.o.) exhibits dose-dependent antitumor efficacy without severe body weight reduction in a melanoma A375 (BRAFV600E) xenograft model and a human melanoma HMVII (NRASQ61K/BRAFG469V) xenograft in rats. [1] In NRAS-mutant melanoma SK-MEL-2 xenograft model, TAK-632 (60 or 120 mg/kg, p.o.) also exhibits potent antitumor efficacy without severe toxicity. [2]